NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

learningcurve2020,

Thank you for reposting your speculation about other DC therapies again and for challenging us to identify the differentiating features of the DCVax-L novel technology.

From the perspectives of patients and investors worldwide, we all would love to hear more about those other DC technologies—please post links from regulatory agencies and independently-reviewed clinical studies so that we can all perform further research.

In the U.S. and the U.K., the DCVax-L platform technology has years of combo data, NWBO has built the capacity to scale production to serve a global market, the NIH is continuing their support, and the clinical evidence-supported implications beyond GBM are promising …

Yesterday, ex highlighted the NIH which is a highly relevant topic to raise—The vast significance of Liau’s work and the further development of the DCVax-L cell-based platform technology in combination with other technologies was/is funded in large part by public dollars awarded through NIH peer-reviewed grants. DCVax-L is already supported by peer-reviewed clinical evidence, but there is much more to the story that is yet to unfold.

If you do some research into the NIH and the FDA, you will discover that not every investigational technology receives the same level of support and not every researcher’s work is recognized by consistent support spanning many consecutive years.

The NCI division of the NIH develops oncology drugs, and FDA approves drugs. There is some connection, and their historical and continuing support is not insignificant …

https://www.bentley.edu/news/new-study-shows-nih-investment-new-drug-approvals-comparable-investment-pharmaceutical

https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016

https://ashpublications.org/ashclinicalnews/news/3819/NIH-Funding-Tied-to-FDA-Approval-of-210-Drugs

Targeted individualized combo therapies are emerging as the defining feature of a new era of oncology. Just look at the impact that PD1 blockade technology has had on the field of oncology in recent years!

https://clinicaltrials.gov/ct2/show/NCT04201873

The U.S. NIH has supported the DCVax-L platform for years, and the NIH renewed its support in 2022 to continue to fund the development of this technology and to fund research into combination therapies.

NIH-funded DCVax-L research is ongoing at UCLA today.

NIH grants are peer-reviewed and the research that NIH funds is highly scrutinized in advance of the award and also intermittently for the term of the various research projects.



https://www.uclahealth.org/cancer/researchers/spores/ucla-spore-brain-cancer/research-projects

https://www.raps.org/news-and-articles/news-articles/2023/8/fda-finalizes-guidance-on-real-world-evidence-in-d


https://www.raps.org/News-and-Articles/News-Articles/2023/9/FDA%E2%80%99s-Califf-Expect-to-see-more-RWE-based-regulato

https://www.fda.gov/media/171667/download

https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/



Mr. Newirth is another DCVax-L survivor well surpassing 10 years following a 2012 diagnosis! Congratulations!

https://www.hawaii.edu/news/2017/03/30/newirth-laker-for-a-day/

2023 Interview:

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://www.theguardian.com/science/2022/nov/17/im-just-carrying-on-vaccine-gives-brain-cancer-patient-years-of-extra-life

https://www.braintumourresearch.org/stories/in-hope/in-hope-stories/kat-charles

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials

https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020



https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter





https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html